<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="26310"><DrugName>Veregen</DrugName><DrugNamesKey><Name id="42753835">Polyphenon E</Name><Name id="42854754">Veregen</Name></DrugNamesKey><DrugSynonyms><Name><Value>Polyphenon E</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>topical polyphenols, Epitome/MediGene/Mitsui</Value></Name><Name><Value>Veregen</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>sinecatechins (warts), Epitome/MediGene/Mitsui</Value></Name><Name><Value>Polyphenon E (topical)</Value></Name><Name><Value>SB-03</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18232">Mitsui Norin Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1045278">Nordic Pharma</Company><Company id="19599">BIAL Group</Company><Company id="25443">Kolon Pharmaceuticals Inc</Company><Company id="14068">Fougera Pharmaceuticals Inc</Company><Company id="31716">Laboratoires Expanscience</Company><Company id="1184769">Aresus Pharma GmbH</Company><Company id="1094837">Kora Healthcare</Company><Company id="1061721">Triton Pharma Inc</Company><Company id="1054098">GC-Rise Pharmaceutical Co Ltd</Company><Company id="1064634">Pharmanova Doo</Company><Company id="1086866">Difa Cooper SPA</Company><Company id="14061">Almirall Prodesfarma SA</Company><Company id="1049942">Solvay Arzneimittel GmbH</Company><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Company id="1061558">Azanta A/S</Company><Company id="14994">Bradley Pharmaceuticals Inc</Company><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Company id="19087">Pierre Fabre SA</Company><Company id="13601">Abbott Laboratories</Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Company id="1060900">Will-Pharma</Company></CompaniesPrimary><CompaniesSecondary><Company id="1031637">Meditrina Pharmaceuticals Inc</Company><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Company id="1038788">Taurus Pharma Gmbh</Company><Company id="1054099">JS Bio Pharm Co Ltd</Company><Company id="17627">Grupo JUSTE</Company><Company id="18232">Mitsui Norin Co Ltd</Company><Company id="24224">MediGene AG</Company><Company id="27325">Epitome Pharmaceuticals Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="26310" type="Drug"><TargetEntity id="283701" type="siDrug">Sinecatechins</TargetEntity></SourceEntity><SourceEntity id="1031637" type="Company"><TargetEntity id="4297888384" type="organizationId">Meditrina Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1038320" type="Company"><TargetEntity id="5035525360" type="organizationId">EIP Eczacibasi Ilac Pazarlama AS</TargetEntity></SourceEntity><SourceEntity id="1038788" type="Company"><TargetEntity id="5034774476" type="organizationId">Taurus Pharma GmbH</TargetEntity></SourceEntity><SourceEntity id="1045278" type="Company"><TargetEntity id="5001350224" type="organizationId">Nordic Pharma SAS</TargetEntity></SourceEntity><SourceEntity id="1049942" type="Company"><TargetEntity id="4298172946" type="organizationId">Abbott Arzneimittel GmbH</TargetEntity></SourceEntity><SourceEntity id="1054098" type="Company"><TargetEntity id="5000698743" type="organizationId">GC-Rise Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1054099" type="Company"><TargetEntity id="5035561510" type="organizationId">JS Bio Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1055579" type="Company"><TargetEntity id="5035461472" type="organizationId">SynCore Biotechnology Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1060900" type="Company"><TargetEntity id="4297453579" type="organizationId">Will Pharma SA</TargetEntity></SourceEntity><SourceEntity id="1061558" type="Company"><TargetEntity id="5035553255" type="organizationId">Azanta Danmark A/S</TargetEntity></SourceEntity><SourceEntity id="1061721" type="Company"><TargetEntity id="5035527215" type="organizationId">Triton Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1064634" type="Company"><TargetEntity id="5036182307" type="organizationId">Pharmanova doo Obrenovac</TargetEntity></SourceEntity><SourceEntity id="1086866" type="Company"><TargetEntity id="4296687821" type="organizationId">Difa Cooper SpA</TargetEntity></SourceEntity><SourceEntity id="1094837" type="Company"><TargetEntity id="5042248713" type="organizationId">Kora Corp Ltd</TargetEntity></SourceEntity><SourceEntity id="1111723" type="Company"><TargetEntity id="5046435399" type="organizationId">Meditrina Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="1184769" type="Company"><TargetEntity id="5068924834" type="organizationId">Aresus Pharma GmbH</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="14061" type="Company"><TargetEntity id="4295889280" type="organizationId">Almirall SA</TargetEntity></SourceEntity><SourceEntity id="14068" type="Company"><TargetEntity id="4297904016" type="organizationId">Fougera Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="14994" type="Company"><TargetEntity id="4295905769" type="organizationId">Bradley Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="17627" type="Company"><TargetEntity id="4298204693" type="organizationId">Juste SAQF</TargetEntity></SourceEntity><SourceEntity id="18232" type="Company"><TargetEntity id="4296405820" type="organizationId">Mitsui Norin Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19087" type="Company"><TargetEntity id="4296343109" type="organizationId">Pierre Fabre SA</TargetEntity></SourceEntity><SourceEntity id="19599" type="Company"><TargetEntity id="5000051815" type="organizationId">BIAL Portela &amp; Ca SA</TargetEntity></SourceEntity><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="24224" type="Company"><TargetEntity id="4295869325" type="organizationId">Medigene AG</TargetEntity></SourceEntity><SourceEntity id="25443" type="Company"><TargetEntity id="4298518662" type="organizationId">Kolon Pharmaceutical</TargetEntity></SourceEntity><SourceEntity id="27325" type="Company"><TargetEntity id="4297659231" type="organizationId">Epitome Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="31716" type="Company"><TargetEntity id="4296091780" type="organizationId">Laboratoires Expanscience SA</TargetEntity></SourceEntity><SourceEntity id="1057" type="ciIndication"><TargetEntity id="D007642" type="MeSH"/><TargetEntity id="-1753854498" type="omicsDisease"/><TargetEntity id="3077" type="siCondition"/></SourceEntity><SourceEntity id="1232" type="ciIndication"><TargetEntity id="D003218" type="MeSH"/><TargetEntity id="-814486215" type="omicsDisease"/><TargetEntity id="959" type="siCondition"/></SourceEntity><SourceEntity id="1764" type="ciIndication"><TargetEntity id="10004146" type="MEDDRA"/><TargetEntity id="D002280" type="MeSH"/><TargetEntity id="-1901373975" type="omicsDisease"/><TargetEntity id="670" type="siCondition"/></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"/><TargetEntity id="-774172916" type="omicsDisease"/><TargetEntity id="865" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Condyloma - US - Dec-2007</FirstLaunched><FirstLaunched>Papillomavirus infection - US - Dec-2007</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1232">Condyloma</Indication><Indication id="1764">Basal cell carcinoma</Indication><Indication id="396">Papillomavirus infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1057">Keratosis</Indication></IndicationsSecondary><ActionsSecondary><Action id="991">Antiviral</Action><Action id="1545">Anticancer</Action><Action id="59620">Unspecified drug target</Action><Action id="15189">Topical dermatological antiviral product</Action></ActionsSecondary><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="1647">Natural product</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-30T09:52:05.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>1999-11-30T12:14:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="24224" linkType="Company"&gt; MediGene&lt;/ulink&gt;, under license from &lt;ulink linkID="27325" linkType="Company"&gt;Epitome Pharmaceuticals&lt;/ulink&gt; (which licensed the drug from &lt;ulink linkID="18232" linkType="Company"&gt;Mitsui Norin&lt;/ulink&gt;), and now marketed  in the US by   &lt;ulink linkID="14994" linkType="Company"&gt;Bradley Pharmaceuticals&lt;/ulink&gt;   and  &lt;ulink linkID="14068" linkType="Company"&gt;Fougera&lt;/ulink&gt; (previously known as Nycomed US) [&lt;ulink linkID="1024802" linkType="Reference"&gt;1024802&lt;/ulink&gt;]  in Germany and Austria by Solvay and &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;   [&lt;ulink linkID="1169478" linkType="Reference"&gt;1169478&lt;/ulink&gt;], [&lt;ulink linkID="1078280" linkType="Reference"&gt;1078280&lt;/ulink&gt;], [&lt;ulink linkID="1121558" linkType="Reference"&gt;1121558&lt;/ulink&gt;], and by  &lt;ulink linkID="1184769" linkType="Company"&gt;Aresus Pharma&lt;/ulink&gt; in the rest of the world, Veregen (Polyphenon E; SB-03) is a 10% ointment formulation of sinecatechins (green tea extract), a  mixture of 8 catechins,  indicated for the treatment of genital warts (papillomavirus infection) and perianal genital warts (condyloma)   [&lt;ulink linkID="348950" linkType="reference"&gt;348950&lt;/ulink&gt;], [&lt;ulink linkID="1430191" linkType="Reference"&gt;1430191&lt;/ulink&gt;], [&lt;ulink linkID="1577779" linkType="Reference"&gt;1577779&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2007, the product was launched in US by marketing licensee  &lt;ulink linkID="14994" linkType="Company"&gt;Bradley Pharmaceuticals&lt;/ulink&gt;   [&lt;ulink linkID="861084" linkType="Reference"&gt;861084&lt;/ulink&gt;], [&lt;ulink linkID="861485" linkType="Reference"&gt;861485&lt;/ulink&gt;]. In February 2009, US licensee, Fougera (previously known as Nycomed US) was also marketing the product in the US [&lt;ulink linkID="1024802" linkType="Reference"&gt;1024802&lt;/ulink&gt;], [&lt;ulink linkID="1032340" linkType="Reference"&gt;1032340&lt;/ulink&gt;]. In March 2007, MediGene  filed an MAA in Europe for genital warts [&lt;ulink linkID="778868" linkType="Reference"&gt;778868&lt;/ulink&gt;]; in March 2010, marketing partner &lt;ulink linkID="1049942" linkType="Company"&gt;Solvay Arzneimittel&lt;/ulink&gt; launched the drug in Germany [&lt;ulink linkID="1078280" linkType="Reference"&gt;1078280&lt;/ulink&gt;]; by August 2010, the drug had been launched in Austria [&lt;ulink linkID="1121558" linkType="Reference"&gt;1121558&lt;/ulink&gt;]. In November 2012, the drug was  launched by Abbot [&lt;ulink linkID="1338898" linkType="Reference"&gt;1338898&lt;/ulink&gt;]. By May 2013, &lt;ulink linkID="1064634" linkType="Company"&gt;Pharmanova Doo&lt;/ulink&gt; had launched the drug for genital warts in Serbia   [&lt;ulink linkID="1420260" linkType="Reference"&gt;1420260&lt;/ulink&gt;]. By January 2013, the drug had been approved in the UK [&lt;ulink linkID="1353852" linkType="Reference"&gt;1353852&lt;/ulink&gt;], where, along with  Ireland, it will be marketed by Medigene's licensee &lt;ulink linkID="1094837" linkType="Company"&gt;Kora Healthcare&lt;/ulink&gt; [&lt;ulink linkID="1543999" linkType="Reference"&gt;1543999&lt;/ulink&gt;].  In August 2013,  &lt;ulink linkID="1086866" linkType="Company"&gt;Difa Cooper&lt;/ulink&gt; had an Italian commercial rights for genital warts [&lt;ulink linkID="1461459" linkType="Reference"&gt;1461459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, Medigene received positive decision on MAA in UK and Italy, and six further EU countries including Ireland, Portugal, Croatia, Latvia, Lithuania and Estonia. At that time, the company expected formal grant of MAA within next ‘months', with a plan to launch the drug in these territories in 2H15 [&lt;ulink linkID="1635290" linkType="Reference"&gt;1635290&lt;/ulink&gt;]; however, no further development was reported since that time.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceutical&lt;/ulink&gt; secured marketing rights for papillomavirus infection in Israel in February 2010 [&lt;ulink linkID="1076578" linkType="Reference"&gt;1076578&lt;/ulink&gt;]. In August 2012, the drug was approved in Israel. At that time, the drug was expected to be launched in 2013 [&lt;ulink linkID="1312363" linkType="Reference"&gt;1312363&lt;/ulink&gt;]. In May 2010, licensee &lt;ulink linkID="1054098" linkType="Company"&gt;GC-Rise Pharmaceutical&lt;/ulink&gt; in China was planning genital warts clinical trials to support an application for approval in the country, with market launch expected at the end of 2013 [&lt;ulink linkID="1097126" linkType="Reference"&gt;1097126&lt;/ulink&gt;].  In February 2011, Pierre Fabre acquired marketing rights in Mexico, Central America, Venezuela and Colombia [&lt;ulink linkID="1169478" linkType="Reference"&gt;1169478&lt;/ulink&gt;]; By February 2011 Abbott had agreed to market  Veregen in Germany, Austria and Switzerland [&lt;ulink linkID="1169478" linkType="Reference"&gt;1169478&lt;/ulink&gt;]. In May 2012, &lt;ulink linkID="19599" linkType="Company"&gt;BIAL Industrial Farmaceutica&lt;/ulink&gt; gained rights to market in Spain and Portugal [&lt;ulink linkID="1287491" linkType="Reference"&gt;1287491&lt;/ulink&gt;]; in June 2012,  BIAL launched the drug in Spain for genital warts [&lt;ulink linkID="1298145" linkType="Reference"&gt;1298145&lt;/ulink&gt;]. In July 2013, the drug was launched in the Netherlands by &lt;ulink linkID="1060900" linkType="Company"&gt;Will-Pharma&lt;/ulink&gt;  [&lt;ulink linkID="1457553" linkType="Reference"&gt;1457553&lt;/ulink&gt;]. In April 2010,  &lt;ulink linkID="1111723" linkType="Company"&gt;Meditrina Pharmaceuticals Ltd&lt;/ulink&gt; (marketing partner  for Greece, Cyprus, Romania and Bulgaria) was planning to file for approval in Greece [&lt;ulink linkID="1087043" linkType="Reference"&gt;1087043&lt;/ulink&gt;], [&lt;ulink linkID="1220574" linkType="Reference"&gt;1220574&lt;/ulink&gt;]. In March 2011, Will-Pharma agreed to market the agent in the Benelux countries [&lt;ulink linkID="1175187" linkType="Reference"&gt;1175187&lt;/ulink&gt;]. In December 2011, regulatory authorities of 17  European countries, including Belgium, Bulgaria, Cyprus, Czech Republic,  Finland, Greece, Hungary, Luxembourg, Norway, Poland, Romania, Slovakia, Slovenia, and Sweden accepted the marketing authorization applications for the drug using the mutual recognition procedure [&lt;ulink linkID="1247765" linkType="Reference"&gt;1247765&lt;/ulink&gt;]; in March 2012,  the marketing authorization applications were positively assessed by the regulatory authorities and the successive launch was anticipated for the end of 2012  [&lt;ulink linkID="1270089" linkType="Reference"&gt;1270089&lt;/ulink&gt;]; in November 2012, marketing authorizations were expected to be granted within 'next few months' in Czech Republic, Greece, and Luxembourg [&lt;ulink linkID="1343488" linkType="Reference"&gt;1343488&lt;/ulink&gt;]; by December 2013,   marketing approval had been granted in Greece and at that time, the company was planning to file marketing authorization applications in nine additional European countries in  2014 [&lt;ulink linkID="1509865" linkType="Reference"&gt;1509865&lt;/ulink&gt;]. By September 2015, launch had taken place in Greece and Romania [&lt;ulink linkID="1696370" linkType="Reference"&gt;1696370&lt;/ulink&gt;]. In May 2012, the marketing authorizations were expected to be granted within 'next few months' [&lt;ulink linkID="1296012" linkType="Reference"&gt;1296012&lt;/ulink&gt;]. By June 2012, the drug had been approved in Poland, Sweden and Norway [&lt;ulink linkID="1298145" linkType="Reference"&gt;1298145&lt;/ulink&gt;]; in December 2013, launch in Norway was planned   in that week and launch in Sweden was expected in early 2014 [&lt;ulink linkID="1509865" linkType="Reference"&gt;1509865&lt;/ulink&gt;]. In September 2011, Pharmanova Doo acquired marketing rights in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania for genital warts [&lt;ulink linkID="1220574" linkType="Reference"&gt;1220574&lt;/ulink&gt;]. In May 2012, launch by Pharmanova in Serbia was expected in the second half of 2012 [&lt;ulink linkID="1296012" linkType="Reference"&gt;1296012&lt;/ulink&gt;]. &lt;ulink linkID="1061558" linkType="Company"&gt;Azanta&lt;/ulink&gt; secured marketing rights in Denmark, Sweden, Norway, Finland, and Iceland for genital and perianal warts with launch planned for the first four countries in early 2013 [&lt;ulink linkID="1300832" linkType="Reference"&gt;1300832&lt;/ulink&gt;].  In August 2012, an MAA was obtained in Denmark and Slovakia  [&lt;ulink linkID="1312363" linkType="Reference"&gt;1312363&lt;/ulink&gt;]. In June 2012, Veregen was approved in France for genital warts [&lt;ulink linkID="1347142" linkType="Reference"&gt;1347142&lt;/ulink&gt;]. In July 2012, the launch in France by Medigene's partner, &lt;ulink linkID="31716" linkType="Company"&gt;Laboratoires Expanscience&lt;/ulink&gt;, was expected in 2013 [&lt;ulink linkID="1305683" linkType="Reference"&gt;1305683&lt;/ulink&gt;]. In November 2012,  the drug was approved in  Belgium, Finland, Slovenia, Hungary, Romania, Bulgaria and Cyprus [&lt;ulink linkID="1338898" linkType="Reference"&gt;1338898&lt;/ulink&gt;]. In March 2013, the drug was approved for marketing in Czech Republic [&lt;ulink linkID="1392403" linkType="Reference"&gt;1392403&lt;/ulink&gt;].  &lt;ulink linkID="1055579" linkType="Company"&gt;Syncore&lt;/ulink&gt; has rights in a  number of territories in Asia, including Taiwan and Japan [&lt;ulink linkID="1393649" linkType="Reference"&gt;1393649&lt;/ulink&gt;]; in March 2013, the NDA for SB-03 was approved by the Taiwan FDA [&lt;ulink linkID="1430191" linkType="Reference"&gt;1430191&lt;/ulink&gt;]. In June 2013, Syncore planned to launch the drug in Taiwan in the second half of 2013 [&lt;ulink linkID="1432797" linkType="Reference"&gt;1432797&lt;/ulink&gt;]; in October 2013, the drug was launched in Taiwan for the treatment of genital warts  [&lt;ulink linkID="1482945" linkType="Reference"&gt;1482945&lt;/ulink&gt;]. In September 2013, &lt;ulink linkID="1061721" linkType="Company"&gt;Triton Pharma&lt;/ulink&gt; received market approval in Canada for  the treatment of genital warts [&lt;ulink linkID="1475303" linkType="Reference"&gt;1475303&lt;/ulink&gt;]; in July 2014, the drug was launched in Canada for external genital and perianal warts [&lt;ulink linkID="1577779" linkType="Reference"&gt;1577779&lt;/ulink&gt;]. In December 2013, &lt;ulink linkID="1038788" linkType="Company"&gt;Taurus Pharma&lt;/ulink&gt; (now &lt;ulink linkID="14061" linkType="Company"&gt;Almirall&lt;/ulink&gt;) planned to market the drug in Germany in January 2014 [&lt;ulink linkID="1739064" linkType="Reference"&gt;1739064&lt;/ulink&gt;],  [&lt;ulink linkID="1506376" linkType="Reference"&gt;1506376&lt;/ulink&gt;]. In December 2013, &lt;ulink linkID="1045278" linkType="Company"&gt;Nordic Pharma&lt;/ulink&gt; planned to launch the drug in the Czech Republic, Poland, Hungary and Slovakia in the first quarter of 2014 [&lt;ulink linkID="1507956" linkType="Reference"&gt;1507956&lt;/ulink&gt;].  In January 2014, the drug was launched in Sweden; in March 2014, the drug was launched in Czech Republic and Slovakia; in April 2014, the drug was launched in Hungary and Poland; by May 2014, the drug had been launched in Norway [&lt;ulink linkID="1562006" linkType="Reference"&gt;1562006&lt;/ulink&gt;]. In June 2014, the drug was launched in Belgium [&lt;ulink linkID="1568435" linkType="Reference"&gt;1568435&lt;/ulink&gt;]. By September 2014, the drug had been launched in Denmark and Finland [&lt;ulink linkID="1593320" linkType="Reference"&gt;1593320&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2009, &lt;ulink linkID="17627" linkType="Company"&gt;Juste&lt;/ulink&gt; secured marketing rights in Spain and Portugal [&lt;ulink linkID="1020336" linkType="Reference"&gt;1020336&lt;/ulink&gt;]; however, in May 2012, BIAL gained these rights [&lt;ulink linkID="1287491" linkType="Reference"&gt;1287491&lt;/ulink&gt;]. In May 2010, &lt;ulink linkID="1054099" linkType="Company"&gt;JS Bio Pharm&lt;/ulink&gt; was  preparing for a submission  for genital warts in  Korea, and expected to launch the agent there in 2012 [&lt;ulink linkID="1097126" linkType="Reference"&gt;1097126&lt;/ulink&gt;]; however, by March 2013, &lt;ulink linkID="25443" linkType="Company"&gt;Kolon Pharmaceuticals&lt;/ulink&gt; had launched the agent in Korea [&lt;ulink linkID="1393649" linkType="Reference"&gt;1393649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;MediGene is also investigating  the drug  as a potential treatment for basal cell carcinoma [&lt;ulink linkID="554163" linkType="Reference"&gt;554163&lt;/ulink&gt;].  In March 2012, Medigene was seeking to outlicense the drug in the signing of additional marketing partnership agreements  at global level [&lt;ulink linkID="1274090" linkType="Reference"&gt;1274090&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;MediGene was developing the drug for the potential treatment of actinic keratosis [&lt;ulink linkID="531183" linkType="reference"&gt;531183&lt;/ulink&gt;]. In April 2004, MediGene initiated a phase II  actinic keratosis trial [&lt;ulink linkID="535707" linkType="reference"&gt;535707&lt;/ulink&gt;]. However, no further development has  been reported since October 2005.&lt;/para&gt;&lt;para&gt;Mitsui's subsidiary, &lt;ulink linkID="1041105" linkType="Company"&gt;Polyphenon Pharma&lt;/ulink&gt;, is  developing an &lt;ulink linkID="60880" linkType="Drug"&gt;oral formulation of the drug&lt;/ulink&gt; for the potential treatment of prostate cancer  and chronic lymphocytic leukemia. The company is also investigating the oral product for the potential treatment of other cancers, including bladder cancer.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In April 2009, Medigene announced that the USPTO granted an extension of 1,300 days for US-05795911 (EP-00842660) which covers the use of topical Polyphenon E for the treatment of genital warts [&lt;ulink linkID="998944" linkType="Reference"&gt;998944&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The active ingredient in Polyphenon E is a  composition of polyphenols extracted from green tea, which inhibit the infectious properties of HPV. Polyphenon E appears to be safe with no apparent local or systemic side effects [&lt;ulink linkID="348950" linkType="reference"&gt;348950&lt;/ulink&gt;], [&lt;ulink linkID="411205" linkType="reference"&gt;411205&lt;/ulink&gt;]. Polyphenol E was patented through 2017; in December 2007, additional applications were pending and the company was to extend patents beyond 2020 if approved [&lt;ulink linkID="861084" linkType="Reference"&gt;861084&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2005, the company submitted an NDA to the FDA for treatment of genital warts [&lt;ulink linkID="625801" linkType="Reference"&gt;625801&lt;/ulink&gt;].   In December 2005, the FDA accepted the NDA for filing [&lt;ulink linkID="638318" linkType="Reference"&gt;638318&lt;/ulink&gt;]; in February 2006, approval was expected later that year [&lt;ulink linkID="650140" linkType="Reference"&gt;650140&lt;/ulink&gt;]. In September 2005, the company expected to launch the drug in the US in 2007 [&lt;ulink linkID="625801" linkType="Reference"&gt;625801&lt;/ulink&gt;]. In June 2006, the FDA extended its review by 90 days until October 2006, because the company, at the FDA's request, had submitted a major amendment to the NDA [&lt;ulink linkID="676502" linkType="Reference"&gt;676502&lt;/ulink&gt;], [&lt;ulink linkID="676682" linkType="Reference"&gt;676682&lt;/ulink&gt;]. In October 2006, the drug was approved in the US [&lt;ulink linkID="737145" linkType="Reference"&gt;737145&lt;/ulink&gt;], [&lt;ulink linkID="736929" linkType="Reference"&gt;736929&lt;/ulink&gt;]; the product was launched in the US in December 2007 [&lt;ulink linkID="861084" linkType="Reference"&gt;861084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt; In September 2005, MediGene expected to file for approval for genital warts  in Europe in 2006 [&lt;ulink linkID="625801" linkType="Reference"&gt;625801&lt;/ulink&gt;]. In March 2007, MediGene  filed an MAA for genital warts. Germany, Austria and Spain would act as the reference member states [&lt;ulink linkID="778868" linkType="Reference"&gt;778868&lt;/ulink&gt;]. In April 2007, the MAA was accepted for review; at that time MediGene hoped to launch the drug in Germany, Austria and Spain in the first half of 2008 [&lt;ulink linkID="785828" linkType="Reference"&gt;785828&lt;/ulink&gt;]. In November 2008,  the company stated that a decision about the application was expected  by the end of  that year or in early 2009 [&lt;ulink linkID="976155" linkType="Reference"&gt;976155&lt;/ulink&gt;]. In July 2009, topical Veregen was assessed positively by German, Austrian, and Spanish authorities for genital warts, guaranteeing it marketing authorization within the following few months. Germany was the reference member state [&lt;ulink linkID="1024802" linkType="Reference"&gt;1024802&lt;/ulink&gt;]. The drug was approved in Germany in September 2009. Launch was expected once a marketing partner was secure, which was expected in  the next few weeks. Approval in Austria and Spain was expected in the coming months [&lt;ulink linkID="1040522" linkType="Reference"&gt;1040522&lt;/ulink&gt;]. In September 2009, launch in Germany was expected in the first half of 2010 [&lt;ulink linkID="1045670" linkType="Reference"&gt;1045670&lt;/ulink&gt;]. In January 2010, MediGene and marketing partner for France, Laboratoires Expanscience,  were planning to initiate the approval process in France for genital warts [&lt;ulink linkID="1160927" linkType="Reference"&gt;1160927&lt;/ulink&gt;]. In March 2010, marketing partner &lt;ulink linkID="1049942" linkType="Company"&gt;Solvay Arzneimittel&lt;/ulink&gt; launched the drug in Germany. By that time, Austrian approval had been received and launch was expected in mid-2010 [&lt;ulink linkID="1078280" linkType="Reference"&gt;1078280&lt;/ulink&gt;]; by August 2010, the drug had been launched in Austria [&lt;ulink linkID="1121558" linkType="Reference"&gt;1121558&lt;/ulink&gt;]. In April 2010, a filing for approval in Greece was in preparation  [&lt;ulink linkID="1087043" linkType="Reference"&gt;1087043&lt;/ulink&gt;]. In March 2011, the drug was approved in Spain; launch was expected in the first quarter of 2012 [&lt;ulink linkID="1180182" linkType="Reference"&gt;1180182&lt;/ulink&gt;]. In March 2011, MediGene planned to file for approval in additional European countries [&lt;ulink linkID="1179294" linkType="Reference"&gt;1179294&lt;/ulink&gt;]; in September 2011, this included Slovenia, with Germany as the reference state [&lt;ulink linkID="1220574" linkType="Reference"&gt;1220574&lt;/ulink&gt;]; in November 2011,  MediGene expected the marketing authorization process for Veregen to be started in additional European countries by the end of 2011 [&lt;ulink linkID="1238882" linkType="Reference"&gt;1238882&lt;/ulink&gt;]; in December 2011, regulatory authorities of 17  European countries, including Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, France, Greece, Hungary, Luxembourg, the Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, and Sweden accepted the marketing authorization applications for the drug using the mutual recognition procedure; at that time, decision for marketing approval was expected by the end of the first quarter of 2012 [&lt;ulink linkID="1247765" linkType="Reference"&gt;1247765&lt;/ulink&gt;]; in March 2012,  the marketing authorization applications were positively assessed by the regulatory authorities and the successive launch was anticipated for the end of 2012 [&lt;ulink linkID="1270089" linkType="Reference"&gt;1270089&lt;/ulink&gt;]; in November 2012, marketing authorizations were expected to be granted within 'next few months' in Czech Republic, Greece, and Luxembourg [&lt;ulink linkID="1343488" linkType="Reference"&gt;1343488&lt;/ulink&gt;]; in December 2013,   marketing approval was granted in Greece and at that time, the company was planning to file marketing authorization applications in nine additional European countries in  2014 [&lt;ulink linkID="1509865" linkType="Reference"&gt;1509865&lt;/ulink&gt;]. in November 2012, market launch in Spain was scheduled for the first half of 2012 [&lt;ulink linkID="1274090" linkType="Reference"&gt;1274090&lt;/ulink&gt;], [&lt;ulink linkID="1270089" linkType="Reference"&gt;1270089&lt;/ulink&gt;]. By March 2012, the drug had been approved in Switzerland, Sweden, Norway and Poland. Launch  in Switzerland was expected later that year [&lt;ulink linkID="1276247" linkType="Reference"&gt;1276247&lt;/ulink&gt;], [&lt;ulink linkID="1289892" linkType="Reference"&gt;1289892&lt;/ulink&gt;]; in August 2012, the drug was launched in Switzerland by Abbott for the treatment of genital warts [&lt;ulink linkID="1615471" linkType="Reference"&gt;1615471&lt;/ulink&gt;, [&lt;ulink linkID="1338898" linkType="Reference"&gt;1338898&lt;/ulink&gt;].  By September 2015, launch had taken place in Greece and Romania [&lt;ulink linkID="1696370" linkType="Reference"&gt;1696370&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, the drug was approved in Serbia for genital warts and launch by Pharmanova was expected in the second half of 2012 [&lt;ulink linkID="1296012" linkType="Reference"&gt;1296012&lt;/ulink&gt;]. In June 2012,  BIAL launched the drug in Spain for genital warts. By that time, the drug had been approved in Poland, Sweden and Norway [&lt;ulink linkID="1298145" linkType="Reference"&gt;1298145&lt;/ulink&gt;];  in December 2013, launch in Norway was planned   in that week and launch in Sweden was expected in early 2014 [&lt;ulink linkID="1509865" linkType="Reference"&gt;1509865&lt;/ulink&gt;].  In June 2012, Veregen was approved in France for genital warts [&lt;ulink linkID="1347142" linkType="Reference"&gt;1347142&lt;/ulink&gt;]. In July 2012, the launch in France by Medigene's partner, &lt;ulink linkID="31716" linkType="Company"&gt;Laboratoires Expanscience&lt;/ulink&gt;, was expected in 2013 [&lt;ulink linkID="1305683" linkType="Reference"&gt;1305683&lt;/ulink&gt;]. In August 2012, Veregen was approved in Israel, Denmark and Slovakia, with launch expected  in 2013 [&lt;ulink linkID="1312363" linkType="Reference"&gt;1312363&lt;/ulink&gt;]; in November 2012,  the drug was approved in Netherlands, Belgium, Finland, Slovenia, Hungary, Romania, Bulgaria and Cyprus [&lt;ulink linkID="1338898" linkType="Reference"&gt;1338898&lt;/ulink&gt;]. In November 2012, Eastern Europe and CIS marketeer, &lt;ulink linkID="1045278" linkType="Company"&gt;Nordic Pharma&lt;/ulink&gt;, planned to launch the drug in the Czech Republic, Slovakia, Poland and Hungary during 2013. Marketing authorization applications for other countries was also in preparation [&lt;ulink linkID="1345331" linkType="Reference"&gt;1345331&lt;/ulink&gt;]. By January 2013, the drug had been approved in the UK [&lt;ulink linkID="1353852" linkType="Reference"&gt;1353852&lt;/ulink&gt;]. In March 2013, the drug was approved for marketing in Czech Republic [&lt;ulink linkID="1392403" linkType="Reference"&gt;1392403&lt;/ulink&gt;].  In April 2013, Pharmanova Doo planned to launched the drug for genital warts in Serbia on April 19, 2013 [&lt;ulink linkID="1404339" linkType="Reference"&gt;1404339&lt;/ulink&gt;].  By May 2013, the drug had been launched in Serbia [&lt;ulink linkID="1420260" linkType="Reference"&gt;1420260&lt;/ulink&gt;]. In July 2013, the drug was launched in the Netherlands by Will-Pharma [&lt;ulink linkID="1457553" linkType="Reference"&gt;1457553&lt;/ulink&gt;].   In August 2013,  MAA for Italy and the remaining European countries was in preparation [&lt;ulink linkID="1461459" linkType="Reference"&gt;1461459&lt;/ulink&gt;]. In December 2013, Nordic Pharma planned to launch the drug in the Czech Republic, Poland, Hungary and Slovakia in the first quarter of 2014 [&lt;ulink linkID="1507956" linkType="Reference"&gt;1507956&lt;/ulink&gt;]. In January 2014, the drug was launched in Sweden; in March 2014, the drug was launched in Czech Republic and Slovakia; in April 2014, the drug was launched in Hungary and Poland; by May 2014, the drug had been launched in Norway [&lt;ulink linkID="1562006" linkType="Reference"&gt;1562006&lt;/ulink&gt;].  In June 2014, the drug was launched in Belgium. At that time, launch in Denmark and Finland was expected within the next few weeks [&lt;ulink linkID="1568435" linkType="Reference"&gt;1568435&lt;/ulink&gt;].  By September 2014, the drug had been launched in Denmark and Finland [&lt;ulink linkID="1593320" linkType="Reference"&gt;1593320&lt;/ulink&gt;].  Later that month, MAA was filed in  Ireland, Italy, Croatia, Latvia, Lithuania, and Estonia. At that time, decision for marketing authorization was expected in the first half of 2015 [&lt;ulink linkID="1598417" linkType="Reference"&gt;1598417&lt;/ulink&gt;]. In February 2015, the company received positive decision on MAA in UK and Italy, and six further EU countries including Ireland, Portugal, Croatia, Latvia, Lithuania and Estonia. At that time, the company expected formal grant of MAA within next ‘months', with a plan to launch the drug in these territories in the second half of 2015 [&lt;ulink linkID="1635290" linkType="Reference"&gt;1635290&lt;/ulink&gt;]; however, no further development was reported in these regions.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In March 2013, the NDA for SB-03 was approved by the Taiwan FDA [&lt;ulink linkID="1430191" linkType="Reference"&gt;1430191&lt;/ulink&gt;]. In June 2013, Syncore planned to launch the drug in Taiwan in the second half of 2013 [&lt;ulink linkID="1432797" linkType="Reference"&gt;1432797&lt;/ulink&gt;]; in October 2013, the drug was launched in Taiwan for the treatment of genital warts   [&lt;ulink linkID="1482945" linkType="Reference"&gt;1482945&lt;/ulink&gt;].  In September 2013, Veregen obtained market approval in Canada for  the treatment of genital warts. At that time, &lt;ulink linkID="1061721" linkType="Company"&gt;Triton Pharma&lt;/ulink&gt; (Medigene's partner) expected to  launch  Veregen during the first half of 2014  [&lt;ulink linkID="1475303" linkType="Reference"&gt;1475303&lt;/ulink&gt;]; in July 2014, the drug was launched in Canada [&lt;ulink linkID="1577779" linkType="Reference"&gt;1577779&lt;/ulink&gt;]. By May 2014, marketing application had been submitted in Turkey and Mexico [&lt;ulink linkID="1562006" linkType="Reference"&gt;1562006&lt;/ulink&gt;]; however, no further development was reported in these regions. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Genital warts&lt;/subtitle&gt;In December 2004, results from the American arm of the phase III trial were released. In 57% of patients treated with topical Veregen, a complete clearance of warts was seen, and in 78% of patients treated with the drug, a disappearance of most, if not all, warts occurred. Recurrence of warts during the 12 weeks of follow-up was observed in 7% of patients [&lt;ulink linkID="575008" linkType="Reference"&gt;575008&lt;/ulink&gt;]. In October 2005, similar data were presented at the 14th Congress of the European Academy of Dermatology and Venerology in London, UK [&lt;ulink linkID="627589" linkType="Reference"&gt;627589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, results from the European arm of the phase III trial were released. The trial  demonstrated high and lasting efficacy of topical Veregen, with low systemic adverse events. In 53% of patients treated with the 15% dose of topical Veregen, a complete clearance of genital warts was seen, and in 78% of all patients treated with the ointment, a disappearance of most, if not all genital warts, was seen. A recurrence of genital warts during the 12 week follow-up period occurred in only 5% of patients. Local skin reactions, such as itching or burning, were mostly mild or moderate [&lt;ulink linkID="530032" linkType="reference"&gt;530032&lt;/ulink&gt;]. In October 2005, similar data were presented at the 14th Congress of the European Academy of Dermatology and Venerology in London, UK [&lt;ulink linkID="627589" linkType="Reference"&gt;627589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, MediGene initiated a second phase III trial. The randomized, double-blind, placebo-controlled trial would enroll 960 patients in the US and Europe. Patients would be administered topical Veregen, three times daily, at two different doses (10 and 15%)  for up to 16 weeks. The endpoint would be the clearance of warts [&lt;ulink linkID="465488" linkType="reference"&gt;465488&lt;/ulink&gt;], [&lt;ulink linkID="478954" linkType="reference"&gt;478954&lt;/ulink&gt;]. In May 2003, MediGene completed enrollment of the required 480 patients in the European arm of the trial, 6 weeks ahead of schedule. At that time, the study was expected to be completed within 7 months, with final results in 2004 [&lt;ulink linkID="490548" linkType="reference"&gt;490548&lt;/ulink&gt;]. In July 2003, MediGene initiated the American arm of the phase III trial. This trial was to enroll 480 patients in 60 hospitals in North and South America. The identically designed arms of the trial were due to complete by the end of 2004 [&lt;ulink linkID="500954" linkType="reference"&gt;500954&lt;/ulink&gt;]. In February 2004, MediGene completed patient enrollment in the American arm of the phase III trial. Full results from the study were expected by year-end 2004, with preliminary results from the European arm of the trial scheduled for release in the first quarter of 2004 [&lt;ulink linkID="522658" linkType="reference"&gt;522658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, MediGene initiated a multicenter, randomized phase III trial [&lt;ulink linkID="395074" linkType="reference"&gt;395074&lt;/ulink&gt;]. The trial was to include 260 patients (50% males, 50% females) in 28 centers in Germany and Russia. The major aim of the double-blind, placebo-controlled study was to test the efficacy of two different formulations of topical Veregen for the treatment of external genital warts [&lt;ulink linkID="395074" linkType="reference"&gt;395074&lt;/ulink&gt;]. Patient recruitment was completed by May 2001, at which time, first results were expected by the end of that year [&lt;ulink linkID="411205" linkType="reference"&gt;411205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 1999, Epitome had initiated a phase II trial [&lt;ulink linkID="348950" linkType="reference"&gt;348950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Actinic keratosis&lt;/subtitle&gt;In April 2004, MediGene initiated a phase II1175187 trial of topical Polyphenon E for actinic keratosis. The randomized, placebo-controlled trial was to assess the efficacy, safety and tolerability of  topical Veregen in 60 patients enrolled at six sites in Germany and Switzerland and was expected to be completed in 2005 [&lt;ulink linkID="535707" linkType="reference"&gt;535707&lt;/ulink&gt;]. In October 2004, enrollment was completed and results were expected to be available in the second quarter of 2005 [&lt;ulink linkID="566399" linkType="Reference"&gt;566399&lt;/ulink&gt;]. In June 2005, results from this trial were released. Topical Veregen demonstrated proof-of-principle; however, the chosen treatment regimen and trial length was not sufficient for complete healing of all lesions. At that time, MediGene planned to define further proceedings for the optimization of the dosage plan [&lt;ulink linkID="610586" linkType="Reference"&gt;610586&lt;/ulink&gt;]. In November 2008, the drug was still listed as in phase II trials on MediGene's website [&lt;ulink linkID="976155" linkType="Reference"&gt;976155&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By February 2004, preclinical studies in basal carcinoma were underway [&lt;ulink linkID="554163" linkType="Reference"&gt;	&lt;/ulink&gt;], [&lt;ulink linkID="526590" linkType="Reference"&gt;526590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data were presented at the 94th AACR meeting, Washington, DC, evaluating Polyphenon E, difluoromethylornithine (DFMO) (qv), 4-hydroxphenylretinamide (4HPR) (qv), 9-cis-retinoic acid (9-cis-RA) and &lt;ulink linkID="3706" linkType="Drug"&gt;nimesulide&lt;/ulink&gt;, for their potential to inhibit the expression of n-cadherin in a premalignant, vertical melanoma cell line (LU-1205) and in a malignant melanoma cell line (83-2c). Cells were pretreated with each chemopreventive agent for 24 h, exposed to a UV dose of 25 mJ/cm2, and the agent treatment continued for 48 h. All five agents were effective in inhibiting n-cadherin at four to five consecutive concentrations in LU-1205 cells, but were ineffective in inhibiting the expression of n-cadherin in 83-2c cells [&lt;ulink linkID="497362" linkType="reference"&gt;497362&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In March 2009, MediGene hoped to conclude European marketing agreements in 2009 [&lt;ulink linkID="996454" linkType="Reference"&gt;996454&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, MediGene was seeking to outlicense the program, and was in talks with  potential partners [&lt;ulink linkID="467351" linkType="reference"&gt;467351&lt;/ulink&gt;]; by December 2005, MediGene had received more than one partnering proposal and was evaluating its options [&lt;ulink linkID="641739" linkType="Reference"&gt;641739&lt;/ulink&gt;]. In January 2006, Bradley   agreed to commercialize topical Veregen in the US.  MediGene retained marketing rights outside the US.  Bradley and MediGene would  later decide whether to codevelop topical Polyphenon E for other dermatological indications [&lt;ulink linkID="647758" linkType="Reference"&gt;647758&lt;/ulink&gt;]. In October 2006, the drug was approved in the US, as a result of which MediGene received a $14 million milestone payment from Bradley [&lt;ulink linkID="737145" linkType="Reference"&gt;737145&lt;/ulink&gt;], [&lt;ulink linkID="736929" linkType="Reference"&gt;736929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, Epitome entered into an agreement with MediGene for the clinical development and commercialization of topical Veregen. MediGene received an exclusive license to develop and commercialize the ointment worldwide for genital warts with the right to grant sublicenses, while Epitome would receive upfront fees, milestone payments and royalties [&lt;ulink linkID="348950" linkType="reference"&gt;348950&lt;/ulink&gt;]. In September 2003, the agreement was expanded to include hyperplasia caused by papilloma viruses [&lt;ulink linkID="504939" linkType="reference"&gt;504939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1997, Epitome  licensed topical Veregen from Mitsui Norin [&lt;ulink linkID="929018" linkType="Reference"&gt;929018&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061558">Azanta A/S</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-12T00:00:00.000Z</StatusDate><Source id="1593320" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-10-01T00:00:00.000Z</StatusDate><Source id="1482945" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14068">Fougera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2009-02-28T00:00:00.000Z</StatusDate><Source id="1024802" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061558">Azanta A/S</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2015-09-21T00:00:00.000Z</StatusDate><Source id="1696370" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061721">Triton Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-07-16T00:00:00.000Z</StatusDate><Source id="1577779" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1615471" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1049942">Solvay Arzneimittel GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-08-05T00:00:00.000Z</StatusDate><Source id="1121558" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1049942">Solvay Arzneimittel GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-03-01T00:00:00.000Z</StatusDate><Source id="1078280" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14994">Bradley Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2007-12-14T00:00:00.000Z</StatusDate><Source id="861485" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="PL">Poland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-04-30T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060900">Will-Pharma</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-06-12T00:00:00.000Z</StatusDate><Source id="1568435" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2015-09-21T00:00:00.000Z</StatusDate><Source id="1696370" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060900">Will-Pharma</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-06-12T00:00:00.000Z</StatusDate><Source id="1568435" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14068">Fougera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2009-02-28T00:00:00.000Z</StatusDate><Source id="1024802" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25443">Kolon Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-20T00:00:00.000Z</StatusDate><Source id="1393649" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060900">Will-Pharma</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-07-29T00:00:00.000Z</StatusDate><Source id="1457553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061558">Azanta A/S</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1064634">Pharmanova Doo</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-05-14T00:00:00.000Z</StatusDate><Source id="1420260" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19599">BIAL Group</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1298145" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14994">Bradley Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2007-12-14T00:00:00.000Z</StatusDate><Source id="861485" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061721">Triton Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-07-16T00:00:00.000Z</StatusDate><Source id="1577779" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061558">Azanta A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-12T00:00:00.000Z</StatusDate><Source id="1593320" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="PL">Poland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-04-30T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1094837">Kora Healthcare</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1543999" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="CY">Cyprus</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="FI">Finland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1094837">Kora Healthcare</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1543999" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1312363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31716">Laboratoires Expanscience</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-06-25T00:00:00.000Z</StatusDate><Source id="1347142" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061558">Azanta A/S</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-06-14T00:00:00.000Z</StatusDate><Source id="1300832" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1064634">Pharmanova Doo</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2011-09-07T00:00:00.000Z</StatusDate><Source id="1220574" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1086866">Difa Cooper SPA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1086866">Difa Cooper SPA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060900">Will-Pharma</Company><Country id="BX">Benelux</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-03-10T00:00:00.000Z</StatusDate><Source id="1175187" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060900">Will-Pharma</Company><Country id="BX">Benelux</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2011-03-10T00:00:00.000Z</StatusDate><Source id="1175187" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1054098">GC-Rise Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-05-10T00:00:00.000Z</StatusDate><Source id="1097126" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="TJ">Tajikistan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1184769">Aresus Pharma GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1764">Basal cell carcinoma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14061">Almirall Prodesfarma SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-02-08T00:00:00.000Z</StatusDate><Source id="1739064" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="KG">Kyrgyzstan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-20T00:00:00.000Z</StatusDate><Source id="1393649" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31716">Laboratoires Expanscience</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1160927" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-20T00:00:00.000Z</StatusDate><Source id="1393649" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="UZ">Uzbekistan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-20T00:00:00.000Z</StatusDate><Source id="1393649" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045278">Nordic Pharma</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17627">Grupo JUSTE</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1232">Condyloma</Indication><StatusDate>2012-05-04T00:00:00.000Z</StatusDate><Source id="1287491" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17627">Grupo JUSTE</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1232">Condyloma</Indication><StatusDate>2012-05-04T00:00:00.000Z</StatusDate><Source id="1287491" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1064634">Pharmanova Doo</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19599">BIAL Group</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-11-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1057">Keratosis</Indication><StatusDate>2005-10-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1057">Keratosis</Indication><StatusDate>2005-10-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1054099">JS Bio Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1094837">Kora Healthcare</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2015-11-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2018-08-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19599">BIAL Group</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-11-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1064634">Pharmanova Doo</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2015-11-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1094837">Kora Healthcare</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="PL">Poland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18232">Mitsui Norin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="929018" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1999-11-30T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1999-11-30T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1038788">Taurus Pharma Gmbh</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2016-02-08T00:00:00.000Z</StatusDate><Source id="1739064" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1999-11-30T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18232">Mitsui Norin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="929018" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1764">Basal cell carcinoma</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1999-11-30T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24224">MediGene AG</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2019-04-17T00:00:00.000Z</StatusDate><Source id="2142573" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="AT">Austria</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-03-01T00:00:00.000Z</StatusDate><Source id="1078280" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2009-09-29T00:00:00.000Z</StatusDate><Source id="1045670" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17627">Grupo JUSTE</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2009-06-23T00:00:00.000Z</StatusDate><Source id="1020336" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17627">Grupo JUSTE</Company><Country id="ES">Spain</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2009-06-23T00:00:00.000Z</StatusDate><Source id="1020336" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19599">BIAL Group</Company><Country id="ES">Spain</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-05-04T00:00:00.000Z</StatusDate><Source id="1287491" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-02-22T00:00:00.000Z</StatusDate><Source id="1076578" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-03-30T00:00:00.000Z</StatusDate><Source id="1276247" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031637">Meditrina Pharmaceuticals Inc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-09-07T00:00:00.000Z</StatusDate><Source id="1220574" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031637">Meditrina Pharmaceuticals Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-09-07T00:00:00.000Z</StatusDate><Source id="1220574" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031637">Meditrina Pharmaceuticals Inc</Company><Country id="CY">Cyprus</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087043" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31716">Laboratoires Expanscience</Company><Country id="FR">France</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1247765" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045278">Nordic Pharma</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1247765" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-03-30T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1054099">JS Bio Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-05-10T00:00:00.000Z</StatusDate><Source id="1097126" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1064634">Pharmanova Doo</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-05-31T00:00:00.000Z</StatusDate><Source id="1296012" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2011-05-18T00:00:00.000Z</StatusDate><Source id="1192592" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-05-18T00:00:00.000Z</StatusDate><Source id="1192592" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061721">Triton Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-04-19T00:00:00.000Z</StatusDate><Source id="1185102" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-03-31T00:00:00.000Z</StatusDate><Source id="1430191" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1247765" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-01-03T00:00:00.000Z</StatusDate><Source id="1353852" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045278">Nordic Pharma</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061558">Azanta A/S</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1312363" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045278">Nordic Pharma</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1392403" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1392403" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-01T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045278">Nordic Pharma</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045278">Nordic Pharma</Company><Country id="PL">Poland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-29T00:00:00.000Z</StatusDate><Source id="1345331" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="PL">Poland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1298145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1298145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061558">Azanta A/S</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-06-14T00:00:00.000Z</StatusDate><Source id="1300832" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1298145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-01-23T00:00:00.000Z</StatusDate><Source id="1256644" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-02-21T00:00:00.000Z</StatusDate><Source id="1169478" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061721">Triton Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2013-09-10T00:00:00.000Z</StatusDate><Source id="1475303" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061721">Triton Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-09-10T00:00:00.000Z</StatusDate><Source id="1475303" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061558">Azanta A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1312363" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="FI">Finland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1094837">Kora Healthcare</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1543999" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1086866">Difa Cooper SPA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-08-06T00:00:00.000Z</StatusDate><Source id="1461459" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087043" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-12-18T00:00:00.000Z</StatusDate><Source id="1509865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="GR">Greece</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-12-18T00:00:00.000Z</StatusDate><Source id="1509865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1111723">Meditrina Pharmaceuticals Ltd</Company><Country id="RO">Romania</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1038788">Taurus Pharma Gmbh</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-12-05T00:00:00.000Z</StatusDate><Source id="1506376" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1055579">SynCore Biotechnology Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2013-03-31T00:00:00.000Z</StatusDate><Source id="1430191" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19599">BIAL Group</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-05-04T00:00:00.000Z</StatusDate><Source id="1287491" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19599">BIAL Group</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-05-04T00:00:00.000Z</StatusDate><Source id="1287491" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1064634">Pharmanova Doo</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1094837">Kora Healthcare</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1064634">Pharmanova Doo</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1094837">Kora Healthcare</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1598417" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-05-27T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-05-27T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061558">Azanta A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2012-06-14T00:00:00.000Z</StatusDate><Source id="1300832" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061558">Azanta A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-06-14T00:00:00.000Z</StatusDate><Source id="1300832" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1057">Keratosis</Indication><StatusDate>2004-04-29T00:00:00.000Z</StatusDate><Source id="535707" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1057">Keratosis</Indication><StatusDate>2004-04-29T00:00:00.000Z</StatusDate><Source id="535707" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2015-09-21T00:00:00.000Z</StatusDate><Source id="1696370" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1764">Basal cell carcinoma</Indication><StatusDate>2004-02-29T00:00:00.000Z</StatusDate><Source id="554163" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2003-07-31T00:00:00.000Z</StatusDate><Source id="500594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="395074" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2007-03-28T00:00:00.000Z</StatusDate><Source id="778868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2003-07-31T00:00:00.000Z</StatusDate><Source id="500594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="395074" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2007-03-28T00:00:00.000Z</StatusDate><Source id="778868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="PL">Poland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-04-30T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-05-27T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2012-11-08T00:00:00.000Z</StatusDate><Source id="1338898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-04-30T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-03-30T00:00:00.000Z</StatusDate><Source id="1180182" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1562006" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1247765" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1057">Keratosis</Indication><StatusDate>2004-04-06T00:00:00.000Z</StatusDate><Source id="531183" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1999-11-30T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27325">Epitome Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348950" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2003-07-31T00:00:00.000Z</StatusDate><Source id="500594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2003-07-31T00:00:00.000Z</StatusDate><Source id="500594" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2005-09-28T00:00:00.000Z</StatusDate><Source id="625801" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2005-09-28T00:00:00.000Z</StatusDate><Source id="625801" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="395074" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="395074" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2002-09-30T00:00:00.000Z</StatusDate><Source id="465488" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2002-09-30T00:00:00.000Z</StatusDate><Source id="465488" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="737145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="737145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18232">Mitsui Norin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="929018" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18232">Mitsui Norin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1232">Condyloma</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="929018" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24224">MediGene AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1040522" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1049942">Solvay Arzneimittel GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2009-09-29T00:00:00.000Z</StatusDate><Source id="1045670" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1049942">Solvay Arzneimittel GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2009-09-29T00:00:00.000Z</StatusDate><Source id="1045670" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1049942">Solvay Arzneimittel GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-03-01T00:00:00.000Z</StatusDate><Source id="1078280" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2142261" linkType="reference" linkID="2142261"&gt;2142261&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2142573" linkType="reference" linkID="2142573"&gt;2142573&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031637">Meditrina Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1042686">Sinphar Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045267">Nordic Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1054098">GC-Rise Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1054099">JS Bio Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1060900">Will-Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1061558">Azanta A/S</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1061721">Triton Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1064634">Pharmanova Doo</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1102660">Women’s Choice Pharmaceuticals LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1104068">Immdal Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1115956">Accelis Pharma</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1184769">Aresus Pharma GmbH</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14061">Almirall Prodesfarma SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17627">Grupo JUSTE</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18232">Mitsui Norin Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19087">Pierre Fabre SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19599">BIAL Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20199">Solvay SA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="24126">Industrial Farmaceutica Cantabria SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24224">MediGene AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>26</CountTotal></Company><Company><Company id="26161">Kolon Industries Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27325">Epitome Pharmaceuticals Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="30256">Eczacibasi Ozgun Kimyasal Urunler Sanayi ve Ticaret AS</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="31716">Laboratoires Expanscience</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>23</CountActive><CountInactive>0</CountInactive><CountTotal>23</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="111080" title="MediGene to develop and commercialize Epitome's Polyphenon E for genital warts and hyperplasia worldwide "/><Deal id="111082" title="Bradley to commercialize MediGene's Polyphenon E in US"/><Deal id="114280" title="Epitome acquires Polyphenon E from Mitsui Norin "/><Deal id="126271" title="Juste to market MediGene's topical polyphenon E in Spain and Portugal"/><Deal id="127128" title="Nycomed US to market MediGene's Veregen in the US"/><Deal id="128167" title="Solvay Arzneimittel to market MediGene's Veregen in Germany, Austria, and Switzerland"/><Deal id="129682" title="Teva to market MediGene's Veregen in Israel"/><Deal id="130064" title="Meditrina to commercialize MediGene's Veregen in Greece, Cyprus, Romania and Bulgaria"/><Deal id="130446" title="GC-Rise to market MediGene's Veregen in China for gential warts "/><Deal id="130448" title="JS Bio Pharm to market MediGene's Veregen for genital warts"/><Deal id="133609" title="Laboratoires Expanscience to promote and distribute MediGene's Veregen ointment in France for genital warts"/><Deal id="133980" title="Pierre Fabre to market and distrubute MediGene's Veregen ointment for genital warts in Mexico, Venezuela, Central America and Colombia"/><Deal id="134130" title="Will-Pharma to market MediGene's Veregen ointment in Belgium, the Netherlands and Luxembourg for genital warts "/><Deal id="134598" title="Triton Pharma to supply and market MediGene's Veregen ointment for genital warts in Canada"/><Deal id="134956" title="SynCore Bio to commercialize MediGene's Veregen to treat genital warts in Asia, New Zealand and Australia excluding China and Korea"/><Deal id="136230" title="Pharmanova to supply and commercialize MediGene's Veregen ointment for genital warts in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania  "/><Deal id="137834" title="EIP to market MediGene's Veregen ointment in Turkey"/><Deal id="139095" title="BIAL Industrial Farmaceutica to commercialize MediGene's Veregen in Spain and Portugal"/><Deal id="139904" title="Azanta to market and distribute MediGene's Veregen for genital warts and perianal warts in the Nordic countries   "/><Deal id="142809" title="Nordic Pharma to supply and market MediGene's Veregen for the treatment of genital warts in Eastern European and CIS Countries "/><Deal id="144428" title="Kolon Pharmaceuticals to market MediGene's Veregen for genital warts"/><Deal id="146183" title="Difa Cooper to supply and commercialize Medigene's Veregen for genital warts in Italy"/><Deal id="147623" title="Taurus to commercialize Medigene's Veregen in Germany  "/><Deal id="149037" title="Kora Healthcare to commercialize Medigene's Veregen against genital warts in the UK and Ireland  "/><Deal id="151573" title="Fougera Pharmaceuticals and WCP to promote Veregen product sales in US  "/><Deal id="157134" title="Accelis Pharma to provide support to promote Fougera Pharmaceuticals' PANDEL and VEREGEN      "/><Deal id="169922" title="Distribution of Veregen (polyphenon E ointment) for genital warts in Germany, Austria, and Switzerland  "/><Deal id="244469" title="Fougera Pharmaceuticals acquires US rights for Medigene's Veregen"/><Deal id="255128" title="Aresus Pharma acquires worldwide excluding US rights for MediGene's Veregen"/></Deals><PatentFamilies><PatentFamily id="1576472" number="EP-00842660" title="Composition for treating condyloma acuminata"/><PatentFamily id="2020348" number="EP-00819433" title="Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin"/><PatentFamily id="2087859" number="US-04840966" title="Method of treating hypertension"/><PatentFamily id="400309" number="WO-03043628" title="Medicament for the treatment of viral skin and tumour diseases"/><PatentFamily id="507750" number="WO-2009126172" title="Resistance to polyphenon E due to increased BCL-2 expression"/><PatentFamily id="773932" number="WO-2007033356" title="Compositions and methods for green tea catechins for modification of detoxification enzymes"/><PatentFamily id="803970" number="WO-2005037300" title="The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Meditrina Pharmaceuticals Inc" id="1031637"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sinphar Group" id="1042686"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nordic Group" id="1045267"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GC-Rise Pharmaceutical Co Ltd" id="1054098"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JS Bio Pharm Co Ltd" id="1054099"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Will-Pharma" id="1060900"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Azanta A/S" id="1061558"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Triton Pharma Inc" id="1061721"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmanova Doo" id="1064634"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Sciences &amp; Peking Union Medical College" id="1066199"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cancer Institute and Hospital, CAMS" id="1089649"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immdal Ltd" id="1104068"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Accelis Pharma" id="1115956"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grupo JUSTE" id="17627"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsui Norin Co Ltd" id="18232"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pierre Fabre SA" id="19087"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BIAL Group" id="19599"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Solvay SA" id="20199"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MediGene AG" id="24224"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Epitome Pharmaceuticals Ltd" id="27325"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eczacibasi Ozgun Kimyasal Urunler Sanayi ve Ticaret AS" id="30256"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratoires Expanscience" id="31716"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>